Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ragni MV et al. - Inhibitor formation is associated with high intensity product exposure, CNS bleeding, African-American race and low frequency of missense mutations. The ideal time to initiate prophylaxis to reduce CNS bleeding and inhibitor formation will require prospective studies.


Exclusive Author Commentary
Margaret V. Ragni, 06/30/09

Hemophilia inhibitor formation is increasingly recognized to be related to early high dose bolus factor treatment, a potent antigenic challenge in very young infants. Because these inhibitors are associated with CNS bleeds, high burden of disease, poor outcomes, and early mortality, prevention is the key. Gene transfer studies in hemophilia mice and dogs suggests that low-level continuous factor VIII or IX may avert inhibitor formation. Whether continuous low level factor VIII or IX in such patients will prevent new inhibitor formation is a critical question, and wil require randomized clinical trials.

Today in Coagulation/Bleeding Dz...keeping you current

Management of the antiphospholipid syndrome: new approaches
International Journal of Clinical Rheumatology, 10/19/09

Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
Annals of Hematology, 10/23/09

Sickle cell disease and stroke
Blood, 10/13/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address